Percutaneous Trigeminal Ganglion Balloon Compression Rhizotomy: Experience in 27 Patients by Strojnik, Tadej & Ŝmigoc, Tomaž
The Scientiﬁc World Journal
Volume 2012, Article ID 328936, 6 pages
doi:10.1100/2012/328936 The  cientiﬁcWorldJOURNAL
Clinical Study
Percutaneous Trigeminal Ganglion Balloon Compression
Rhizotomy:Experience in 27 Patients
Tadej Strojnik1,2 and Tomaˇ z ˆ Smigoc1
1Department of Neurosurgery, University Clinical Centre Maribor, Ljubljanska 5, SI-2000 Maribor, Slovenia
2Department of Neurosurgery, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia
Correspondence should be addressed to Tadej Strojnik, t.strojnik@amis.net
Received 2 October 2011; Accepted 1 November 2011
Academic Editor: Allan Gottschalk
Copyright © 2012 T. Strojnik and T. ˆ Smigoc. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. Percutaneous ganglion balloon compression (PBC) is a minimally invasive procedure for treatment of trigeminal
neuralgia. Materials and Methods. Twenty-seven (19 female and 8 male) patients, who presented with classical symptoms of
trigeminalneuralgia,wereincluded.Agerangedfrom34to91years(median62years),33procedureswereperformed.Durationof
the symptoms ranged from 1 year to 30 years (median 5 years). Results. After the procedure, pain relief was reported in 25 (93%)
patients. In two patients, the pain remained the same. The pain free period ranged from 2 to 74 months (median 15 months).
A mean duration of analgesia was longer in patients with ideal pear shape of balloon at the time of the procedure compared
to nonideal shape (P = 0.01). No major complications occurred in our group of patients. Conclusions. Percutaneous trigeminal
ganglion balloon compression is a safe, simple, and eﬀective method for temporary pain relief in a selective group of trigeminal
neuralgia patients.
1.Introduction
Thediagnosisandmedicalmanagementoftrigeminalneura-
lgia (TN) can be one of the most frustrating and rewarding
challenges in neurosurgical practice. Exact cause of it is
not known, and various types of treatment modalities are
possible, and yet no surgical treatment for TN meets
ideal requirements [1]. TN is described as sudden, usually
unilateral, severe, brief, stabbing recurrent episodes of pain
withinthedistributionofoneormorebranchesoftrigeminal
nerve, which has a profound eﬀect on quality of life
[2, 3]. Patients pain severity correlate with reduced daily
functioning and poor health status [4, 5]. All that prompting
the search for new operation techniques and the shearing of
experiences with existing ones, among them percutaneous
balloon compression (PBC) is promising.
According to the classiﬁcation of the International Head-
ache Society, TN can be classiﬁed as classical or idiopathic
and on symptomatic or secondary [3, 6]. Burchiel presented
diagnostic classiﬁcation which is driven by the patient’s his-
tory, where type 1 TN is predominantly episodic and sharp
and type 2 TN is constant, dull, and burning in nature [7, 8].
Pathophysiology is not completely understood. Ephaptic
conduction caused by segmental demyelination and artiﬁcial
synapse formation is speculated to be the cause [9–11]. In
ephaptic transmission signal from large-diameter partially
demyelinated A ﬁbers conduct to small-diameter poorly
myelinated A-delta and unmyelinated nociceptive C ﬁbers,
which results in paroxysmal facial pain. In pathogenesis of
TN neurovascular conﬂict is seen—vascular compression
of the trigeminal nerve at the root entry zone that is
most frequently caused by superior cerebellar artery. Other
possible causes of demyelination may be tumor of posterior
cranial fossa, plaque within brainstem in multiple sclerosis
(MS), basilar impression, aneurysm, arteriovenous (AV)
malformation, atherosclerosis, and natural aging [9, 11].
Diagnosis of TN is based on history. Classical symptoms
of TN include paroxysmal, “electric” pain in the trigeminal
distribution on one side of the face; trigger areas that,
when stimulated by cold air, washing, speaking, eating, or2 The Scientiﬁc World Journal
touch, bring this classic type of pain; periods of remission
and exacerbation; pain that is typically more severe in
the morning and absent during sleep; periodic pain relief
when treated with an adequate trial of carbamazepine.
The physical exam is generally normal in TN. Trigeminal
sensory deﬁcits, bilateral involvement, abnormal trigeminal
reﬂexes, and herpetic vesicles are signs of symptomatic
TN. Magnetic resonance imaging (MRI) is used not only
to identify patients with structural causes—tumors, MS,
but also to demonstrate neurovascular conﬂict [6, 9]. In
diﬀerential diagnostic of TN herpes zoster, dental disease,
orbital disease, giant cell arteritis, and intracranial tumor are
considered. In one study there were reported six (15.4%)
cases of unnecessary dental procedures by patient with
TN [3]. The American Academy of Neurology (AAN)
and the European Federation of Neurological Societies
(EFNS) Guidelines on TN treatment from 2008 recommend
medical treatment with carbamazepine and oxcarbazepine
or lamotrigine and baclofen as ﬁrst option [6]. When
patients are refractory to medical treatment or side eﬀects
of medications exceed patients’ tolerability, early surgical
therapy is recommended. Various modalities of surgical
treatment are possible, from major intracranial operation to
minimally invasive percutaneous techniques. Because of the
longest duration of pain freedom, as a ﬁrst surgical option
microvascular decompression (MVD) is recommended. But
it presents major intracranial operation, which may not be
suitablefor older, debilitated patients. MVD is also presented
with risk of major neurological complications and mortality.
Due to their minimally invasive nature and possibility to
repeat it are percutaneous procedures widely used methods
for the surgical treatment of TN, mostly in cases not
suitable for MVD, when patients are not willing to have
MVD or they are refractory to previous surgical treatment.
One of them is percutaneous ganglion balloon compression
(PBC). It was ﬁrst introduced by Mullan and Lichtor in
1983 [12]. Since then it represent eﬀective, low-cost, simple
therapeutic modality for treatment of TN. Compression by
PBCselectivelyinjuresthemyelinpresentinlargemyelinated
ﬁbers that mediate light touch. PBC is selective for large
ﬁbers but not selective for pain originating from a particular
trigeminal division [13]. Compression selectively preserves
the small unmyelinated ﬁbers that mediate pain and tem-
perature sensation. It does not injure the axons themselves.
Balloon compression reduces the sensory neuronal input,
thus turning oﬀ the trigger to the neuropathic trigeminal
pain.TheDepartmentofNeurosurgeryofUniversityClinical
Center(UCC)MariboristheﬁrstandonlycenterinSlovenia
that has used PBC for treatment of TN. In this article our
experience with PBC is presented.
2.MaterialsandMethods
Within a ten-year period (from 2000 until 2010), 33PBC
were performed in 27 patients at the Department of Neu-
rosurgery of UCC Maribor. There were 19 female and 8 male
patients. Age ranged from 34 years to 91 years (median 62
years). Patients included in the study were suﬀering from
classical symptoms of trigeminal neuralgia, 22 cases had
Figure 1: Through the entry point—2.5cm lateral to the corner of
the mouth, a specially designed needle with thin stylet was passed
into foramen ovale.
nature of type 1 TN and 11 cases of type 2 TN. One patient
had bilateral trigeminal neuralgia, 16 patients were aﬀected
on the right side and 10 on the left side. All patients were
treated with medications prior PBC without suﬃcient pain
relief.ThemediandurationofthesymptomsbeforePBCwas
5 years, ranged from one year to 30 years, 5 patients had
already undergone surgery, among them three previously
had MVD, one alcohol rhizotomy, and one section of the
trigeminal sensory root. On 27 patients 33 procedures were
performed—three patients had two procedures on the same
side and one patient had four procedures, three on the same
side and one on the other side.
2.1. Short Procedure Description. For PBC Mullan percu-
taneous trigeminal ganglion microcompression set (Cook
Vascular Inc., US) was used. Patient was positioned supine
on the operating table. Procedures were done in general
anesthesiawithashort-actinganestheticagent.X-raycontrol
of pyramid and foramen ovale was performed. A specially
designed 14-gauge needle with thin stylet was passed 6cm
into the depth towards foramen ovale through entry point
located 2.5cm lateral to the corner of the mouth (Figure 1).
Foramen ovale was entered with dull tip of stylet. X-ray
control ofneedle position was made and the balloon catheter
was introduced through the needle and navigated into
Meckel’s cave. The position of tip was conﬁrmed by using a
C-armﬂuoroscopicimageintensiﬁerinbothanteroposterior
and lateral views. About 1mL of water-soluble contrast
(iohexol) was injected to inﬂate the balloon, until ideal pear
shapeoftheballoonwasacquired(Figure 2).Thedurationof
inﬂation depended upon the duration of the disease (longer
course of disease, longer time of inﬂation). After one to ﬁve
minutes the balloon was deﬂated and the needle and catheter
were removed simultaneously. Firm pressure was applied to
the cheek for some minutes. The patients were discharged
after an overnight stay.
2.2. Patient Database and Statistical Analysis. The medical
and surgical records of all patients were retrospectivelyThe Scientiﬁc World Journal 3
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Figure 2: The balloon catheter was introduced through the needle
and navigated into Meckel’s cave. The shape showed if the balloon
was in the appropriate position: (a) ideal pear shape; (b) not ideal
shape.
reviewed and analyzed. The following data were collected:
gender, age, side of trigeminal neuralgia, duration of symp-
toms prior PBC in years, previous surgical procedures,
time of balloon inﬂation in minutes, the shape of the
balloon, number of consecutive PBC, type of pain, com-
plications during and after procedure, hypoesthesia after
PBC, duration of analgesia after PBC in months, need for
analgesics after 12 months, and procedures done after PBC.
Descriptive statistical analysis was performed and patients’
parameters were statistically analyzed with Fischer exact test
for descriptive variables, independent Student’s t-test for
numeric variables and Kaplan-Meier analysis for duration of
analgesia. Statistically signiﬁcant were values with P<0.05.
The software used was SPSS 17.0.
3. Results
3.1. Outcome. After one or more procedures pain relief was
reported in 25 (93%) of patients. In two patients the pain
remainedthesame.Pain-freeperiodinremaining25patients
ranged from 2 to 74 months with mean value 15 ± 13.2
months (Figure 3).
Twelve months after the PBC patients needed less analge-
sics than before PBC in 22 (67%) cases and no analgesics
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Figure 3: Kaplan-Meier plot illustrating pain-free proportion of
patients after a percutaneous trigeminal ganglion balloon compres-
sion. Mean pain-free period was 15 months.
in one (3%) case. In 8 (24%) cases the needed dose of
analgesic was the same and in two (6%) cases patients
needed more analgesic than before PBC. In the case of pain
recurrence a brief period of increased medical therapy was
suﬃcient to control the pain. In refractory patients another
procedure was performed. After repeated procedure patients
remained pain-free with minimal medication for additional
6–12 months. There were 22 cases of type 1 TN and 11 cases
of type 2 TN. We found no statistically signiﬁcant diﬀerence
between types of TN in respect to gender or age. Number
of previous procedures was higher in type 2 TN (6 out of
11 in type 2 TN and 6 out of 22 in type 1 TN), but it was
not signiﬁcant. The mean duration of symptoms prior PBC
w a si nt y p e1T Ns e v e ny e a r sa n di nt y p e2T Ne i g h ty e a r s .
Hypoesthesia after PBC was found in 13 (59%) cases of type
1 TN and six (55%) in type 2 TN. Duration of analgesia after
PBC was in type 1 TN 15 ± 15.4 months and in type 2 TN
12 ± 7.6 months (P = 0.38). Analgesic consumption after 12
m o n t h sw a sn o n eo rl o w e ri nt y p e1T Ni n1 7c a s e s( 7 7 % )
and in type 2 TN in six cases (55%; P = 0.06).
3.2. Correlation between Parameters and Outcome. We ana-
lyzed correlation between clinical parameters before PBC
and outcome of the procedure (duration of analgesia and
use of analgesic 12 months after PBC). Outcomes were
compared in dependence of gender, age of patients (60
y e a r sa n dy o u n g e rv e r s u s6 1y e a r sa n do l d e r ) ,d u r a t i o no f
symptoms (5 years and less versus 6 and more years), and
previous surgical treatment. None of the parameters showed
statistically signiﬁcant correlation with outcomes. However,
mean duration of analgesia was longer in females, younger
patients and shorter duration of symptoms before PBC.
According to previous surgical treatment mean duration of
analgesia was almost the same with or without previous
surgical treatment. Use of analgesic at 12 months was
generally with all parameters lower than before PBC. Results
aresummarizedinTable 1.Additionally,correlationbetween
the length of balloon inﬂation and the duration of pain-free
period was not statistically signiﬁcant (P = 0.76).4 The Scientiﬁc World Journal
Table 1: Patients’ parameters and outcome of the procedure.
Mean duration of
analgesia (months)
Use of analgesic at 12 month
None or less The same or more
Gender Male (n = 8) 9 ± 7.7 5 3
Female (n = 19) 16 ± 15.7 13 6
Age
60 and younger
(n = 14) 16 ± 18.8 8 6
61 and older (n = 19) 13 ± 7.5 15 4
Duration of
symptoms
5 years and less
(n = 17) 16 ± 16.4 14 3
6 years and more
(n = 16) 12 ± 9.1 9 7
Previous surgical
treatment
Yes (n = 12) 15 ± 8.8 8 4
No (n = 21) 14 ± 15.5 15 6
3.3. Complaints and Complications. No major complications
occurred in our group of patients. Non-ideal shape of
the balloon was reported in 8 (24%) procedures. A mean
duration of analgesia was longer in patients with ideal pear-
shape of balloon at the time of the procedure (17.4 ± 13.7
months) compared to non-ideal shape (4.4 ± 4.0 months)
(P = 0.01). In seven out of 33 procedures premature balloon
rupture occurred, without any immediate consequences for
the patients. Three patients developed cheek hematoma; this
subsided with cold compression. In nineteen cases mild to
moderate degree of transient ipsilateral facial sensory loss—
numbness was noted.
4. Discussion
The patient’s characteristics in our group of TN patients
were comparable to other studies: female predominance,
advanced age, and more commonly aﬀected right side are
commonly reported [9]. Procedures were performed by
Mullan’s technique with some modiﬁcation as described in
Section 2 [12]. During procedure it is important that, when
inﬂated, the shape of balloon must be pear shaped. This
shape has, according to Mullan and other researches, signif-
i c a n ti m p a c to nt h eo u t c o m e[ 14–16]. Pear-shaped balloon
correspond to the inner anatomy of the Meckel cave—the
dural protrusion surrounding the trigeminal ganglion and
the distal part of the trigeminal root [14]. This was also
the case in our group of patients where better outcome
was noted in those patients with ideal shape of the balloon.
Another important predictor is also the duration of balloon
compression. Al-Banyan et al. have found that long balloon
inﬂation times of 20min signiﬁcantly improve the duration
of pain-free period [17]. But on the other hand, longer
compression times are associated with higher complication
rates [15]. We can conclude that for satisfactory outcome
during compression balloon should be pear-shaped and
duration of compression need to be long enough to give us
acceptable correlation between duration of pain-free period
and side eﬀects. Immediate pain relief after PBC is high. In
our study it was similar to other studies, where immediate
pain relief is reported in 83 to 100% of cases. Mullan and
Lichtor report initial relief in all patients except in one [12].
Skirving and Dan reported in their large study with 531PBC,
initial pain relief in 521PBC except in one and 9 procedure
failures[18],100%initialreliefisreportedbyNatarajan[19].
Average duration of pain-free period with PBC is around
2 years, and recurrence rate for TN varies among studies.
Mean pain-free period in our group of patients was within
the range reported in other larger studies where mean
duration of pain-free period ranges from 7.3 months to 30
months. Shorter duration is reported in studies with only
recurrent TN [20, 21]. Reports on recurrence rate are depen-
dent of duration of follow-up period. Unfortunately there
is lack of long-term studies that could give us information
about long-lasting outcome after PBC. Mullan and Lichtor
predicted 20% recurrence rate over 5 years [12]. Two larger
studies Baabor and Perez-Limonte with 230PBC, reported
15% recurrence after 3 years [22], and Skirving and Dan
reported 31.9% of recurrence in entire study lasting for 20
years [18]. Higher recurrence is reported by Kouzounias et
al. with 50% recurrence at 21 months, and in both studies
with recurrent TN (45.5% and 64%) [20, 21, 23].
Use of analgesic one year after PBC is lower than before.
In our study majority of patients after one year needed no
or less analgesic than before PBC. In studies where cases of
repeated PBC in refractory TN were analyzed, the outcome
as immediate pain relief and duration of analgesia was
comparable with ﬁrst-time procedures [20, 21, 24].
Some studies have shown longer duration of analgesia in
type 1 TN [24, 25]; in others authors did not ﬁnd diﬀerences
between both types [26]. In our group of patients the out-
come, according to duration of analgesia and postprocedure
analgesic consumption, was better in type 1 TN, but not
statistically signiﬁcant. However, in our group of type 2
TN were more cases with previous procedures and longer
durationofsymptomsbeforePBC,whicharetwofactorsthat
are by some authors connected with worse outcome.
Currently there are no clinical parameters that could cer-
tainlypredictwhichpatientswouldhavebetteroutcomeafter
PBC. In our study only some mild diﬀerences were shown.The Scientiﬁc World Journal 5
Age, gender of patient, aﬀected trigeminal division, and side
of TN, have shown in all studies no statistically signiﬁcant
impact on outcome after PBC [3, 15, 17]. On the other hand,
shorter duration of symptoms before PBC (less than 5 years)
is considered to be a favorable prognostic factor. Longer
preprocedure symptoms duration is connected with higher
risk of recurrence and complication rate [15, 19, 24]. If
compression on trigeminal root and ganglion is excluded by
MRI or patient is not willing to undergone MVD, PBC could
be one of the ﬁrst options. The history of previous treatment
shouldnotbeobstacleforPBCanditshouldbeconsideredin
patientswithrecurrentTN[3,13,17,23].Ontheotherhand,
some studies have shown slightly higher complication rate in
recurrent cases [15]. Postprocedure numbness is a predictor
of longer duration of analgesia and less recurrence [3, 15].
Conclusions about predictive factors from our study are not
reliable, due to retrospective nature of the study and small
number of patients.
In PBC the incidences of complications is low and major
complications are rare. In our study there were no major
complication and no permanent morbidity, this corresponds
to results of other studies. PBC can relieve pain in any of
the three trigeminal divisions [12]. During procedure, when
the foramen ovale is engaged, short-lasting bradycardia and
the masseter and pterygoid muscles contraction are noted
[15]. With additional use of local anesthetic we can lower
the number of cardiovascular events [27]. One important
issue is also premature balloon rupture which might aﬀect
the outcome of the procedure. The possible causes of this
complication can include material fatigue, careless handling
of the catheter before the introduction, or inﬂation with
too much contrast medium. After procedure, hypoesthesia,
is reported by almost all patients and it is usually mild to
moderate and transient [13, 14, 19, 26, 28]. The goal of PBC
is to injure the myelinated ﬁbers that mediate the “trigger”
for the lancinating pain of TN, and hypoesthesia is therefore
the known consequence [3]. In some cases hypoesthesia is
prolonged and permanent or even dysesthesias can occur
[3, 13, 15, 19, 20, 29]. In severe and rare cases anaesthesia
dolorosa has also been reported in the literature [20, 26]. So
only light compression is safer in terms of dysesthesias, but
will result in recurrences whereas a ﬁrm compression will
eliminate recurrences but increase the risk of dysesthesias
[12]. Having postoperative hypoesthesia is usually better
tolerated in patients than recurrent pain [16]. One study
suggest that with intraluminal monitoring of compression
pressure and limiting the duration of compression it is
possible to reduce the incidence of dysesthesias, severe
numbness, and masseter weakness after PBC [28]. Other
possible rare complication in PBC are masseter muscle
weakness with mastication weakness, loss of corneal reﬂex,
corneal keratitis, altered taste sensation, herpes perioralis
eruption, hearing loss, transient sudden blindness, abducens
weakness, transient trochlear nerve palsy, loss of olfactory
sense, changes in lacrimation, AV ﬁstula, subarachnoid
hemorrhage, and aseptic meningitis [3, 9, 15]. Generally
PBC bears little discomfort for patient and only short
hospitalization (2-3 days) [12, 16, 29].
5. Conclusions
To sum up, when patients fail medical management, either
due to intolerable side eﬀects or loss of eﬀect, early surgical
options should be considered. There is no absolute guideline
for selecting the best procedure for patients. Patient selection
and procedure selection consider (1) the patient’s medical
condition, (2) previous procedures, and (3) the patient’s
willingness to accept the associated risks and beneﬁts of each
procedure.
Percutaneous techniques are recommended for elderly
patients with higher operative risk factors. In general, PBC
should be reserved for patients rejecting or not suitable for
MVD.ContraindicationsforPBCarerare.Cautionisneeded
inthecaseofthecontrastagentallergybecauseruptureofthe
balloon catheter can occur. In case of recurrence after PBC,
the patient may be treated with carbamazepine. It provides
satisfactory relief at a tolerably low dose. If carbamazepine
fails, PBC may be repeated. Advantages of PBC with
comparisonofothersurgicaloptions fortreatmentofTNare
minimalinvasiveness,highportionofpain-freepatientsafter
procedure, and low incidence of complications.
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